The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...

Aspirin did not impact CVD incidence; however, risk may be higher in those with metastatic, hematological and lung cancer and ...

SAN ANTONIO, October 16, 2024--bioAffinity VP served on expert panel to update flow cytometry guidelines for unique ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...

BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

As immunotherapy makes breakthrough progress in the treatment of small cell lung cancer (SCLC), predicting treatment outcomes ...